Imexon for Relapsed Follicular and Aggressive Lymphomas
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Amplimexon (imexon for injection) is
effective in the treatment of indolent and aggressive lymphomas that have progressed after
treatment with standard therapies.